消瘀康胶囊联合尤瑞克林治疗急性脑梗死的效果分析

Analysis of the Effect of Xiaoyukang Capsule Combined with Urinary Kallidinogenase in the Treatment of Acute Cerebral Infarction

目的研究消瘀康胶囊联合尤瑞克林治疗急性脑梗死的疗效。方法选择2019年1月—2023年1月大理白族自治州人民医院收治的92例急性脑梗死患者作为研究对象,按照干预方式的不同将其分为对照组和观察组,各46例。对照组采用尤瑞克林治疗,观察组在对照组治疗的基础上联用消瘀康胶囊治疗。计算两组治疗有效率,检测两组的临界压力(CP)、脉搏波数(Wv)、最小血流量(Qmin)、动态阻抗(DR)、脑血管外周阻力(R)和颈动脉最小血流速度(Vmin),且检测血清生长分化因子15(GDF-15)、CXC趋化因子16(CXCL-16)、正五聚蛋白3(PTX3)和单核细胞趋化蛋白1(MCP-1)水平。结果观察组的治疗有效率明显高于对照组,差异有统计学意义(P<0.05);治疗前,两组的CP、Wv、Qmin、DR、R和Vmin比较,差异无统计学意义(P>0.05),治疗后,两组的CP、Wv、Qmin、DR、R和Vmin均明显改善,且观察组的CP、Wv、Qmin、DR、R和Vmin改善明显优于对照组,差异有统计学意义(P<0.05);治疗前,两组的血清GDF-15、CXCL-16、PTX3和MCP-1水平比较,差异无统计学意义(P>0.05),治疗后,两组的血清GDF-15、CXCL-16、PTX3和MCP-1水平均明显降低,且观察组的血清GDF-15、CXCL-16、PTX3和MCP-1水平明显低于对照组,差异有统计学意义(P<0.05)。治疗前,两组Barthal指数比较,差异无统计学意义(P>0.05),治疗后,两组Barthal指数评分均明显升高,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组的不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论采用消瘀康胶囊联合尤瑞克林治疗能明显提高急性脑梗死的疗效,改善脑血流动力学,减轻炎症反应,提高患者日常生活能力,且安全性高。

Objective To investigate the effect of Xiaoyukang capsule combined with Urinary Kallidinogenase in the treatment of acute cerebral infarction.Methods A retrospective analysis was conducted on the clinical data of 92 patients with acute cerebral infarction admitted to the People's Hospital of Dali Bai Autonomous Prefecture from January 2019 to January 2023.They were divided into two groups according to different intervention methods.The control group used Urinary Kallidinogenase,while the observation group was treated with Xiaoyukang capsules in combination with the control group.The effective rates of two treatment groups were calculated,critical pressure(CP),pulse wave number(Wv),minimum bloodflow(Qmin),dynamic impedance(DR),peripheral resistance of cerebral vessels(R)and minimum bloodflow velocity of carotid arteries(Vmin)were measured in the two groups,and serum levels of growth differentiation factor 15(GDF-15),CXC chemokine 16(CXCL-16),pentameric protein 3(PTX3)and Monocyte chemotactic protein 1(MCP-1)were measured.Results The effective rate of the observation group was significantly higher than control group(P<0.05).Before treatment,there was no significant difference in CP,Wv,Qmin,DR,R,and Vmin between the two groups(P>0.05).After treatment,the CP,Wv,Qmin,DR,R,and Vmin of the two groups were significantly improved(P<0.05),and the CP,Wv,Qmin,DR,R,and Vmin of the observation group were significantly better than those of the control group(P<0.05).Before treatment,there was no significant difference in serum levels of GDF-15,CXCL-16,PTX3,and MCP-1 between the two groups(P>0.05).After treatment,the serum levels of GDF-15,CXCL-16,PTX3,and MCP-1 in both groups were significantly reduced(P<0.05),and the serum levels of GDF-15,CXCL-16,PTX3,and MCP-1 in the observation group were significantly lower than those in the control group(P<0.05).Before treatment,there was no statistically significant difference in Barthal index between the two groups(P>0.05).After treatment,the Barthal index scores of the two groups significantly increased(P<0.05),and the observation group was higher than the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion The combination of Xiaoyukang Capsules and Urinary Kallidinogenase can significantly improve the therapeutic effect of acute cerebral infarction,improve cerebral hemodynamics,reduce inflammatory reactions,improve patients'daily living ability,and have high safety.